A Ca 2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)
Ozempic and Wegovy both use semaglutide, but Wegovy has a higher dose
While some individuals may tolerate treatment without immediate complications, skipping laboratory testing can result in: Missed contraindications (e.g., thyroid abnormalities, pancreatitis risk) Undetected metabolic conditions (e.g., insulin resistance, liver disease) Poorly tailored dosing and monitoring There are limited scenarios where recent lab data (within 36 months) may suffice, but initiating treatment without any clinical baseline is generally considered incomplete care
Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, et al